Nimbus is applying deep computational chemistry expertise throughout the drug discovery and development process to create novel small molecules for substantial and underserved human diseases in metabolism, oncology and immunology. At our core, we are a drug discovery company, enabled by our privileged partnership with Schrödinger, our computational chemistry co-founder.
Our arsenal of in silicocapabilities is unmatched in the industry and extends into all aspects of discovery and early development. We couple novel insights from human genetics and recent advances in biology with our experience and expertise in computational chemistry and drug discovery to select targets that are an excellent fit for our platform capabilities and could yield important new medicines for disease areas with high unmet need.
Our expertise extends from our nimble team of experts through a unique ecosystem shaped by drug discovery partnerships with industry leaders and technology partnerships with industry, academia and government. Together, we can find molecules de novo and support their development through to registration.